Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

23 Sep 2024 07:00

RNS Number : 2035F
MyCelx Technologies Corporation
23 September 2024
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

23 September 2024

MYCELX Technologies Corporation

("MYCELX" or the "Company")

Trading Update

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, announces a trading update following changes to the customer's project timeline at one of its REGEN installations for a customer in Nigeria.

 

As set out in the announcement dated 23 August 2024, the Company highlighted that the outturn for the current financial year would be dependent on projects meeting delivery timelines with one significant project in particular expecting to be recognised in December when factory acceptance testing was due to be completed.

 

Subsequent to successful achievement of the last project milestone three weeks ago for the above-mentioned project, the Company has just recently been made aware by the customer that the next major milestone has been delayed for several weeks. While not unusual for a project of this size and complexity, this delay comes at a critical time in terms of MYCELX's ability to deliver its equipment as scheduled. The Board recognises that there is now a strong possibility this delay will affect the Company's factory acceptance testing in mid-December, and revenue recognition in 2024, and as a result, the Board has made the prudent decision to shift anticipated revenue from the project from Q4 2024 to Q1 2025. The Company has accordingly revised its 2024 revenue forecast of $9.5 million to $4.5-$5.0 million and will recognise the project value of $5.4 million in 2025.

 

There will be no loss of revenue for the Company and minimal impact to the forecasted year end cash balance given MYCELX will continue to receive milestone payments that keep the project cash flow positive despite the delay. The Company will be announcing its Interim Results in the coming days.

 

The Company looks forward to working closely with its partners in Nigeria to successfully deliver this project and continuing its momentum in REGEN adoption in the oil and gas market.

 

Connie Mixon, CEO, commented:

 

"While this project will be marginally delayed, there will be no significant effect on the business since revenue is simply shifting from Q4 2024 to Q1 2025 and impact to the Company's cash balance at year end is minimal. We look forward to completion of this project which is our fourth installation in Nigeria where our technology is enabling producers to achieve their goals of better water treatment and a cleaner environment.

 

We plan to announce our Interim Results over the coming days, which will give the market further insight into the progress across our core markets."

 

For further information, please contact:

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nominated Adviser and Sole Broker)

Henry Fitzgerald-O'Connor

Charlie Hammond

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKNBBPBKKNCB
Date   Source Headline
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock
10th Jun 20135:16 pmRNSChange of Main Office Address
3rd Jun 20133:19 pmRNSTotal Voting Rights
28th May 20135:02 pmRNSHolding(s) in Company
28th May 20132:54 pmRNSDirector/PDMR Shareholding
24th May 20138:52 amRNSHolding(s) in Company
14th May 20132:14 pmRNSResult of Annual Meeting
14th May 20137:00 amRNSOperational Update & Directorate Change
9th May 20137:00 amRNSExercise of Warrant
23rd Apr 201312:49 pmRNSApplication for Block Admission
19th Apr 20137:00 amRNSAnnual Financial Report/Directorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.